ストックスクリーナーアプリを入手
1.63
4.49%
0.07
アフターアワーズ：
1.63
前日終値:
$1.56
開ける：
$1.6
24時間の取引高:
594.27K
Relative Volume:
2.81
時価総額：
$36.52M
収益：
-
当期純損益:
$-58.20M
株価収益率:
-0.6262
EPS:
-2.603
ネットキャッシュフロー:
$-47.21M
1週間 パフォーマンス:
+41.74%
1か月 パフォーマンス:
+46.85%
6か月 パフォーマンス:
+23.48%
1年 パフォーマンス:
+20.74%
1日の値動き範囲:
$1.56
$1.67
1週間の範囲:
$1.12
$1.68
52週間の値動き範囲:
$0.9612
$1.78
Boundless Bio Inc Stock (BOLD) Company Profile
Compare BOLD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.63 | 34.96M | 0 | -58.20M | -47.21M | -2.603 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-05-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-22 | 開始されました | Guggenheim | Buy |
| 2024-04-22 | 開始されました | Leerink Partners | Outperform |
| 2024-04-22 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Boundless Bio Inc (BOLD) 最新ニュース
12 Health Care Stocks Moving In Tuesday's Intraday SessionAdagio Medical Holdings (NASDAQ:ADGM), Allog - Benzinga
Tuesday's session: gap up and gap down stocks - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio to terminate San Diego lease, agrees to $10 million payment - Investing.com Australia
Boundless Bio Terminates Major Long-Term San Diego Lease - TipRanks
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Chipmakers Recap: Is Boundless Bio Inc in a long term uptrend2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
GODN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
EPS Watch: Is Boundless Bio Inc subject to activist investor interest2026 Volume Leaders & Safe Entry Point Alerts - baoquankhu1.vn
Aug Decliners: What hedge funds are buying Akanda Corp2026 Price Targets & Weekly High Potential Stock Alerts - baoquankhu1.vn
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Swing Trade: Is EFOI forming higher highs and higher lows2026 Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NVNO PE Ratio & Valuation, Is NVNO Overvalued - Intellectia AI
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
APUS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Volume Recap: Will Boundless Bio Inc face regulatory challenges2026 WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
What analysts say about Boundless Bio Inc stockPortfolio Gains Report & Reliable Intraday Trade Plans - baoquankhu1.vn
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: Emerging Therapies, ROA, Molecules, Companies and Future Outlook - Barchart
Checkpoint Inhibitors Competitive Landscape & Pipeline 2026: - openPR.com
Stop Loss: Can Boundless Bio Inc ride the EV wave2026 Gainers & Long Hold Capital Preservation Plans - baoquankhu1.vn
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
If You Invested $1,000 in SeaStar Medical Holding Corp (ICU) - Stock Titan
BOLD Technical Analysis & Stock Price Forecast - Intellectia AI
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
Boundless Bio: Underestimated Biotech With First-In-Class EcDNA Targeted Kinesin Degrader - Seeking Alpha
Risks Report: Is Boundless Bio Inc stock a smart retirement pick2026 Price Momentum & Technical Confirmation Trade Alerts - baoquankhu1.vn
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 - The Manila Times
Inside a novel cancer drug aiming at ecDNA-positive, high-risk breast tumors - Stock Titan
Bear Alert: Can Boundless Bio Inc ride the EV waveInsider Buying & Weekly Momentum Picks - baoquankhu1.vn
Trend Review: Can Boundless Bio Inc maintain its current growth rateWeekly Trade Recap & Weekly High Return Stock Opportunities - baoquankhu1.vn
FORTY Should I Buy - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
02386 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Gains Report: What are the analyst revisions for Boundless Bio IncIs RAAQU stock a good investment in YEARWeekly Profit Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
ASTI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio posts smaller-than-expected Q4 loss - MSN
CVU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AHRT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Leerink reiterates Market Perform on Boundless Bio stock at $4 - Investing.com
Boundless Bio Reports Q4 and Full Year 2025 Financial Results, Highlights Progress of KOMODO-1 Clinical Trial and BBI-940 Program - Minichart
03268 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
02400 Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MGRD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share - AlphaStreet
Boundless Bio Inc (BOLD) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):